Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium/Formoterol vs Tiotropium in COPD
NCT03275116Phase 4Unknown
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aclidinium and formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Static hyperinflation at 24 hours. Status: unknown.
02
Drugs
aclidiniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03275116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275116.